USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has launched a global registration, phase 2 clinical trial investigating the efficacy of a potential new breast cancer therapy called ARX788.

The trial is currently recruiting breast cancer patients whose cancer has metastasized (spread to other areas of the body) and whose tumors show increased levels of a protein called human epidermal growth factor receptor 2 (HER2). Participants must also have experienced resistance or disease progression while on treatment plans containing T-DM1, and/or T-DXd, and/or tucatinib, which are typically prescribed for HER2-positive breast cancer patients.

To continue reading this story, click here.